Lincoln Pharmaceuticals

Drug maker Lincoln Pharmaceuticals on Thursday said its consolidated net profit jumped by 24.51 per cent to Rs 23.67 crore in the April-June quarter of 2024-25 compared to Rs 19.01 crore in the year-ago quarter. Total income of the Ahmedabad-bnased company rose by 10 per cent to Rs 157.69 crore in the quarter under review from Rs 143.31 crore in the first quarter of 2023-24. Its operating profit (EBITDA) rose by 16.65 per cent to Rs 33.14 crore in the quarter from Rs 28.41 crore in Q1FY24. Both domestic and export operations have shown robust growth and the company is confident to enhance profitability and margins going forward, the company said in a statement. With focused growth strategies and business expansion plans for value added products and expanding to newer markets, the company is targeting revenue of Rs 750 crore in FY26, it said in the earnings statement. Lincoln Pharmaceuticals shares closed 0.95 per cent down at Rs 652.75 on BSE.

The acquisition along with capacity expansion and modernisation entails an investment of Rs 30 crore which Lincoln Pharma will fund through internal accruals

Firm to expand product basket, prepares for entry into European market

Receives Germany's GMP certification for its Khatraj plant, can sell to all 27 EU markets

The company has upgraded its manufacturing facility at Khatraj near Ahmedabad with Rs 30-crore investment

The drug is painless and gives faster relief to the patients, Lincoln Pharma said

The Ondansetron Oral Spray has been launched in the dosage form of 0.2ml equivalent to 2mg and 0.4 ml equivalent to 4mg,